Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy

Abstract Background A total of 10%–20% of patients develop long-term toxicity following radiotherapy for prostate cancer. Identification of common genetic variants associated with susceptibility to radiotoxicity might improve risk prediction and inform functional mechanistic studies. Methods We conducted an individual patient data meta-analysis of six genome-wide association studies (n = 3871) in men of European ancestry who underwent radiotherapy for prostate cancer. Radiotoxicities (increased urinary frequency, decreased urinary stream, hematuria, rectal bleeding) were graded prospectively. We used grouped relative risk models to test associations with approximately 6 million genotyped or imputed variants (time to first grade 2 or higher toxicity event). Variants with two-sided Pmeta less than 5 × 10−8 were considered statistically significant. Bayesian false discovery probability provided an additional measure of confidence. Statistically significant variants were evaluated in three Japanese cohorts (n = 962). All statistical tests were two-sided. Results Meta-analysis of the European ancestry cohorts identified three genomic signals: single nucleotide polymorphism rs17055178 with rectal bleeding (Pmeta = 6.2 × 10−10), rs10969913 with decreased urinary stream (Pmeta = 2.9 × 10−10), and rs11122573 with hematuria (Pmeta = 1.8 × 10−8). Fine-scale mapping of these three regions was used to identify another independent signal (rs147121532) associated with hematuria (Pconditional = 4.7 × 10−6). Credible causal variants at these four signals lie in gene-regulatory regions, some modulating expression of nearby genes. Previously identified variants showed consistent associations (rs17599026 with increased urinary frequency, rs7720298 with decreased urinary stream, rs1801516 with overall toxicity) in new cohorts. rs10969913 and rs17599026 had similar effects in the photon-treated Japanese cohorts. Conclusions This study increases the understanding of the architecture of common genetic variants affecting radiotoxicity, points to novel radio-pathogenic mechanisms, and develops risk models for testing in clinical studies. Further multinational radiogenomics studies in larger cohorts are worthwhile.

[1]  P. Donnelly,et al.  A new multipoint method for genome-wide association studies by imputation of genotypes , 2007, Nature Genetics.

[2]  J. Stanford,et al.  Long-term functional outcomes after treatment for localized prostate cancer. , 2013, The New England journal of medicine.

[3]  R. Eeles,et al.  Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects , 2005, British Journal of Cancer.

[4]  M. Sydes,et al.  A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  E. Schadt,et al.  A Nasal Brush-based Classifier of Asthma Identified by Machine Learning Analysis of Nasal RNA Sequence Data , 2017, bioRxiv.

[6]  Hans L. Oestreicher,et al.  Supplementary notes , 2018, Much Ado about Nothing.

[7]  Joseph O Deasy,et al.  STROGAR – STrengthening the Reporting Of Genetic Association studies in Radiogenomics , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[8]  H. Deckmyn,et al.  Platelet adhesion to collagen. , 2011, Thrombosis research.

[9]  J. Ioannidis,et al.  Meta-analysis methods for genome-wide association studies and beyond , 2013, Nature Reviews Genetics.

[10]  Jen-Tzung Chien,et al.  Radiation Therapy Outcomes Models in the Era of Radiomics and Radiogenomics: Uncertainties and Validation. , 2018, International journal of radiation oncology, biology, physics.

[11]  Alison M. Dunning,et al.  Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype , 2009, Nature Reviews Cancer.

[12]  Jon Wakefield,et al.  A Bayesian measure of the probability of false discovery in genetic epidemiology studies. , 2007, American journal of human genetics.

[13]  M. Kanai,et al.  Genome-wide association study identifies 112 new loci for body mass index in the Japanese population , 2017, Nature Genetics.

[14]  M. Hauer-Jensen,et al.  Radiation enteropathy—pathogenesis, treatment and prevention , 2014, Nature Reviews Gastroenterology &Hepatology.

[15]  David Gillatt,et al.  10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. , 2017, The New England journal of medicine.

[16]  W. De Neve,et al.  Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients. , 2004, International journal of radiation oncology, biology, physics.

[17]  Richard Stock,et al.  Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer , 2016, EBioMedicine.

[18]  Yurii S. Aulchenko,et al.  ProbABEL package for genome-wide association analysis of imputed data , 2010, BMC Bioinformatics.

[19]  LENT SOMA scales for all anatomic sites. , 1995, International journal of radiation oncology, biology, physics.

[20]  H. Ostrer,et al.  A 2-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of urinary symptoms after radiotherapy for prostate cancer. , 2013, The Journal of urology.

[21]  Alison M Dunning,et al.  A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1 , 2014, Nature Genetics.

[22]  D. Dearnaley,et al.  Evaluating the efficacy of statins and ACE-inhibitors in reducing gastrointestinal toxicity in patients receiving radiotherapy for pelvic malignancies. , 2012, European journal of cancer.

[23]  Dennis J. Hazelett,et al.  The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers , 2016, Cancer Epidemiology, Biomarkers & Prevention.

[24]  Annie Gao,et al.  Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial , 2016, The Lancet. Oncology.

[25]  Gabor T. Marth,et al.  A global reference for human genetic variation , 2015, Nature.

[26]  J. Rosenbloom,et al.  Narrative Review: Fibrotic Diseases: Cellular and Molecular Mechanisms and Novel Therapies , 2010, Annals of Internal Medicine.

[27]  F. Cunningham,et al.  The Ensembl Variant Effect Predictor , 2016, Genome Biology.

[28]  J. Michael Cherry,et al.  ENCODE data at the ENCODE portal , 2015, Nucleic Acids Res..

[29]  Zachary A. Szpiech,et al.  Genome-wide association studies in diverse populations , 2010, Nature Reviews Genetics.

[30]  Michael Boehnke,et al.  LocusZoom: regional visualization of genome-wide association scan results , 2010, Bioinform..

[31]  Daniel Marbach,et al.  Fast and Rigorous Computation of Gene and Pathway Scores from SNP-Based Summary Statistics , 2016, PLoS Comput. Biol..

[32]  P. D. de Groot,et al.  Synergism between platelet collagen receptors defined using receptor-specific collagen-mimetic peptide substrata in flowing blood. , 2010, Blood.

[33]  M. Spitz,et al.  Mutagen sensitivity has high heritability: evidence from a twin study. , 2006, Cancer research.

[34]  K. D. Sørensen,et al.  Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci , 2018, Nature Genetics.

[35]  Matthias Egger,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies , 2007, PLoS medicine.

[36]  Annie Gao,et al.  Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. , 2012, The Lancet. Oncology.

[37]  Data production leads,et al.  An integrated encyclopedia of DNA elements in the human genome , 2012 .

[38]  A. Molteni, J. E. Moulder, E. F. Cohen, W. F. Ward, B,et al.  Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blocker , 2000 .

[39]  Andrew P Morris,et al.  Multi-ethnic genome-wide association study identifies novel locus for type 2 diabetes susceptibility , 2016, European Journal of Human Genetics.

[40]  M. Sydes,et al.  Implementing the UK Medical Research Council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[41]  M. Barry,et al.  The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. , 1992, The Journal of urology.

[42]  J. Vaňásek,et al.  Late toxicity after conformal and intensity‐modulated radiation therapy for prostate cancer: Impact of previous surgery for benign prostatic hyperplasia , 2010, International journal of urology : official journal of the Japanese Urological Association.

[43]  B. Becker,et al.  How meta-analysis increases statistical power. , 2003, Psychological methods.

[44]  W. Vainchenker,et al.  Inhibition of angiotensin I-converting enzyme induces radioprotection by preserving murine hematopoietic short-term reconstituting cells. , 2004, Blood.

[45]  Y. Li,et al.  Trans-ethnic genome-wide association studies: advantages and challenges of mapping in diverse populations , 2014, Genome Medicine.

[46]  P. Lambin,et al.  The REQUITE project: validating predictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve quality of life in cancer survivors. , 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).

[47]  E. Cohen,et al.  Noncontinuous use of angiotensin converting enzyme inhibitors in the treatment of experimental bone marrow transplant nephropathy , 1997, Bone Marrow Transplantation.

[48]  ENCODEConsortium,et al.  An Integrated Encyclopedia of DNA Elements in the Human Genome , 2012, Nature.

[49]  P. Lambin,et al.  Data-Based Radiation Oncology: Design of Clinical Trials in the Toxicity Biomarkers Era , 2017, Front. Oncol..

[50]  R. Stock,et al.  Genetic predictors of adverse radiotherapy effects: the Gene-PARE project. , 2006, International journal of radiation oncology, biology, physics.

[51]  N G Burnet,et al.  Radiosensitivity, radiogenomics and RAPPER. , 2006, Clinical oncology (Royal College of Radiologists (Great Britain)).

[52]  H. Ostrer,et al.  Genome-wide association study identifies a region on chromosome 11q14.3 associated with late rectal bleeding following radiation therapy for prostate cancer. , 2013, Radiotherapy and Oncology.

[53]  Richard Stock,et al.  A 2-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of erectile dysfunction following radiation therapy for prostate cancer. , 2013, International journal of radiation oncology, biology, physics.

[54]  J. Hendry,et al.  Deterministic rather than stochastic factors explain most of the variation in the expression of skin telangiectasia after radiotherapy. , 2002, International journal of radiation oncology, biology, physics.

[55]  Y. Yamada,et al.  Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[56]  John T. Wei,et al.  Quality of life and satisfaction with outcome among prostate-cancer survivors. , 2008, The New England journal of medicine.

[57]  J. Ioannidis,et al.  STrengthening the REporting of Genetic Association Studies (STREGA)--an extension of the STROBE statement. , 2009, Genetic epidemiology.

[58]  E. Gore,et al.  Decreased risk of radiation pneumonitis with incidental concurrent use of angiotensin-converting enzyme inhibitors and thoracic radiation therapy. , 2012, International journal of radiation oncology, biology, physics.

[59]  M. Sydes,et al.  Late Gastrointestinal Toxicity After Dose-Escalated Conformal Radiotherapy for Early Prostate Cancer: Results From the UK Medical Research Council RT01 Trial (ISRCTN47772397) , 2010, International journal of radiation oncology, biology, physics.

[60]  A. Dunning,et al.  Standardized Total Average Toxicity score: a scale- and grade-independent measure of late radiotherapy toxicity to facilitate pooling of data from different studies. , 2012, International journal of radiation oncology, biology, physics.

[61]  Nawaid Usmani,et al.  The Prediction of Radiotherapy Toxicity Using Single Nucleotide Polymorphism-Based Models: A Step Toward Prevention. , 2015, Seminars in radiation oncology.

[62]  S. Tucker,et al.  How much could the radiotherapy dose be altered for individual patients based on a predictive assay of normal-tissue radiosensitivity? , 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[63]  P. Carroll,et al.  The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy. , 1995, International journal of radiation oncology, biology, physics.